The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands

Published:2023-10-05 Issue: Volume: Page:1-9
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Ouaddouh C.¹,Duijster J.W.¹^ORCID,Lieber T.¹,van Hunsel F.P.A.M.¹²^ORCID

Affiliation:

1. Vaccine Team, Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, Netherlands

2. Faculty of Science and Engineering, FarmacoTherapie, Epidemiologie en Economie Groningen Research Institute of Pharmacy, Groningen, the Netherlands

Funder

Ministry of Health, Welfare and Sport

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2267971

Reference43 articles.

1. Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination

2. COVID-19 Vaccination for People with Comorbidities

3. European Medicines Agency (EMA). Consideration on core requirements for RMPs of COVID-19 vaccines - coreRMP19 guidance v3.1. vol. EMA/PRAC/709308/2022. 2022.

4. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

5. Infections and autoimmunity – friends or foes?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP